BIA's response to the Department of Health and Social Care's consultation on NICE recommendations - charging and appeal panels

The BIA has responded to the Department of Health and Social Care's consultation on NICE recommendations. 
 
Our submission focuses on the proposals to introduce charges for companies applying for NICE technology appraisals. We argue that the introduction of charges:
•    should be delayed until the full impact of Brexit on UK life sciences is known
•   could disadvantage SMEs
•   could create inequalities in patient access to new medicines in the UK and disproportionately affect patients with very rare conditions.
 
This response builds on our previous submission to NICE on the same issue in September 2016.